{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:19:11Z","timestamp":1787019551279,"version":"build-2736575974"},"reference-count":50,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,7,11]]},"abstract":"<jats:title>Key Points<\/jats:title>\n                  <jats:p>TKIs impair B-cell immune responses in CML through off-target inhibition of kinases important for B-cell signaling. Our results call for close monitoring of patients on TKI to assess the long-term impact of impaired B-cell function.<\/jats:p>","DOI":"10.1182\/blood-2012-11-465039","type":"journal-article","created":{"date-parts":[[2013,5,30]],"date-time":"2013-05-30T00:52:03Z","timestamp":1369875123000},"page":"227-238","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":102,"title":["Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling"],"prefix":"10.1182","volume":"122","author":[{"given":"Hugues","family":"de Lavallade","sequence":"first","affiliation":[{"name":"Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom;"},{"name":"Department of Haematological Medicine, King\u2019s College Hospital NHS Foundation Trust, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Khoder","sequence":"additional","affiliation":[{"name":"Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Hart","sequence":"additional","affiliation":[{"name":"Immunology Section, Division of Infectious Diseases, Imperial College London at Chelsea and Westminster Hospital, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anushruti","family":"Sarvaria","sequence":"additional","affiliation":[{"name":"Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom;"},{"name":"Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Sekine","sequence":"additional","affiliation":[{"name":"Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom;"},{"name":"Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Alsuliman","sequence":"additional","affiliation":[{"name":"Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Mielke","sequence":"additional","affiliation":[{"name":"University of W\u00fcrzburg, W\u00fcrzburg, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Bazeos","sequence":"additional","affiliation":[{"name":"Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Stringaris","sequence":"additional","affiliation":[{"name":"Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ali","sequence":"additional","affiliation":[{"name":"Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragana","family":"Milojkovic","sequence":"additional","affiliation":[{"name":"Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Foroni","sequence":"additional","affiliation":[{"name":"Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aristeidis","family":"Chaidos","sequence":"additional","affiliation":[{"name":"Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nichola","family":"Cooper","sequence":"additional","affiliation":[{"name":"Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Gabriel","sequence":"additional","affiliation":[{"name":"Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Apperley","sequence":"additional","affiliation":[{"name":"Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Belsey","sequence":"additional","affiliation":[{"name":"Toxicology Unit, Department of Clinical Biochemistry, King\u2019s College Hospital NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Flanagan","sequence":"additional","affiliation":[{"name":"Toxicology Unit, Department of Clinical Biochemistry, King\u2019s College Hospital NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Goldman","sequence":"additional","affiliation":[{"name":"Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Shpall","sequence":"additional","affiliation":[{"name":"Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kelleher","sequence":"additional","affiliation":[{"name":"Immunology Section, Division of Infectious Diseases, Imperial College London at Chelsea and Westminster Hospital, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Marin","sequence":"additional","affiliation":[{"name":"Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katayoun","family":"Rezvani","sequence":"additional","affiliation":[{"name":"Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"20","key":"2019111818505035500_B1","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J Clin Oncol"},{"issue":"24","key":"2019111818505035500_B2","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"issue":"24","key":"2019111818505035500_B3","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"issue":"8","key":"2019111818505035500_B4","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/sj.leu.2403401","article-title":"Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro.","volume":"18","author":"Cwynarski","year":"2004","journal-title":"Leukemia"},{"issue":"10","key":"2019111818505035500_B5","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1182\/blood-2006-04-018705","article-title":"Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections.","volume":"108","author":"Mumprecht","year":"2006","journal-title":"Blood"},{"issue":"6","key":"2019111818505035500_B6","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1182\/blood-2004-07-2527","article-title":"Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner.","volume":"105","author":"Seggewiss","year":"2005","journal-title":"Blood"},{"issue":"3","key":"2019111818505035500_B7","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1182\/blood-2004-01-0027","article-title":"Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance.","volume":"105","author":"Wang","year":"2005","journal-title":"Blood"},{"issue":"10","key":"2019111818505035500_B8","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.4049\/jimmunol.181.10.6955","article-title":"Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors.","volume":"181","author":"Larmonier","year":"2008","journal-title":"J Immunol"},{"issue":"9","key":"2019111818505035500_B9","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/nm.2438","article-title":"Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido.","volume":"17","author":"Balachandran","year":"2011","journal-title":"Nat Med"},{"issue":"3","key":"2019111818505035500_B10","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.clim.2008.02.006","article-title":"The Src\/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro.","volume":"127","author":"Blake","year":"2008","journal-title":"Clin Immunol"},{"issue":"3","key":"2019111818505035500_B11","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1582-4934.2009.00500_1.x","article-title":"Nilotinib inhibits the Src-family kinase LCK and T-cell function in vitro.","volume":"13","author":"Blake","year":"2009","journal-title":"J Cell Mol Med"},{"issue":"5b","key":"2019111818505035500_B12","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1111\/j.1582-4934.2008.00234.x","article-title":"Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling.","volume":"12","author":"Chen","year":"2008","journal-title":"J Cell Mol Med"},{"issue":"10","key":"2019111818505035500_B13","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.exphem.2008.05.002","article-title":"Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens.","volume":"36","author":"Fei","year":"2008","journal-title":"Exp Hematol"},{"issue":"2","key":"2019111818505035500_B14","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.exphem.2008.09.013","article-title":"Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo.","volume":"37","author":"Fraser","year":"2009","journal-title":"Exp Hematol"},{"issue":"8","key":"2019111818505035500_B15","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1158\/1078-0432.CCR-07-4393","article-title":"Profound inhibition of antigen-specific T-cell effector functions by dasatinib.","volume":"14","author":"Weichsel","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2019111818505035500_B16","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1038\/leu.2011.135","article-title":"Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation.","volume":"25","author":"Kreutzman","year":"2011","journal-title":"Leukemia"},{"issue":"8","key":"2019111818505035500_B17","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/leu.2009.46","article-title":"Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy.","volume":"23","author":"Mustjoki","year":"2009","journal-title":"Leukemia"},{"issue":"4","key":"2019111818505035500_B18","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/leu.2012.348","article-title":"Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy.","volume":"27","author":"Mustjoki","year":"2013","journal-title":"Leukemia"},{"issue":"10","key":"2019111818505035500_B19","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1172\/JCI28546.","article-title":"Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis.","volume":"116","author":"Paniagua","year":"2006","journal-title":"J Clin Invest"},{"issue":"7","key":"2019111818505035500_B20","first-page":"762","article-title":"Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia.","volume":"88","author":"Steegmann","year":"2003","journal-title":"Haematologica"},{"issue":"13","key":"2019111818505035500_B21","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1182\/blood-2011-01-327932","article-title":"Imatinib mesylate directly impairs class switch recombination through down-regulation of AID: its potential efficacy as an AID suppressor.","volume":"119","author":"Kawamata","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2019111818505035500_B22","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/leu.2010.11","article-title":"Lck is a key target of imatinib and dasatinib in T-cell activation.","volume":"24","author":"Lee","year":"2010","journal-title":"Leukemia"},{"issue":"12","key":"2019111818505035500_B23","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","article-title":"Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.","volume":"110","author":"Rix","year":"2007","journal-title":"Blood"},{"issue":"2","key":"2019111818505035500_B24","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3324\/haematol.2010.032664","article-title":"Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host.","volume":"96","author":"de Lavallade","year":"2011","journal-title":"Haematologica"},{"issue":"5","key":"2019111818505035500_B25","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.bbmt.2010.08.002","article-title":"Humoral and cellular immunity to primary H1N1 infection in patients with hematologic malignancies following stem cell transplantation.","volume":"17","author":"Garland","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2019111818505035500_B26","doi-asserted-by":"crossref","first-page":"8212","DOI":"10.4049\/jimmunol.178.12.8212","article-title":"Loss of discrete memory B cell subsets is associated with impaired immunization responses in HIV-1 infection and may be a risk factor for invasive pneumococcal disease.","volume":"178","author":"Hart","year":"2007","journal-title":"J Immunol"},{"issue":"3","key":"2019111818505035500_B27","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/bmc.2796","article-title":"Simple methodology for the therapeutic drug monitoring of the tyrosine kinase inhibitors dasatinib and imatinib.","volume":"27","author":"Birch","year":"2013","journal-title":"Biomed Chromatogr"},{"issue":"5","key":"2019111818505035500_B28","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1023\/A:1025373601374","article-title":"Common variable immunodeficiency patient classification based on impaired B cell memory differentiation correlates with clinical aspects.","volume":"23","author":"Piqueras","year":"2003","journal-title":"J Clin Immunol"},{"issue":"5","key":"2019111818505035500_B29","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.4049\/jimmunol.175.5.3262","article-title":"Regulation of aged humoral immune defense against pneumococcal bacteria by IgM memory B cell.","volume":"175","author":"Shi","year":"2005","journal-title":"J Immunol"},{"issue":"9460","key":"2019111818505035500_B30","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(05)70931-4","article-title":"Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial.","volume":"365","author":"Bocchia","year":"2005","journal-title":"Lancet"},{"issue":"3","key":"2019111818505035500_B31","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1182\/blood-2003-03-0954","article-title":"A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia.","volume":"103","author":"Cathcart","year":"2004","journal-title":"Blood"},{"issue":"5","key":"2019111818505035500_B32","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1182\/blood.V95.5.1781.005k46_1781_1787","article-title":"Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses.","volume":"95","author":"Pinilla-Ibarz","year":"2000","journal-title":"Blood"},{"issue":"11","key":"2019111818505035500_B33","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1038\/sj.leu.2404858","article-title":"Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study.","volume":"21","author":"Rojas","year":"2007","journal-title":"Leukemia"},{"issue":"2","key":"2019111818505035500_B34","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jaci.2004.10.048","article-title":"The loss of IgM memory B cells correlates with clinical disease in common variable immunodeficiency.","volume":"115","author":"Carsetti","year":"2005","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"2019111818505035500_B35","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1084\/jem.20022020","article-title":"Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen.","volume":"197","author":"Kruetzmann","year":"2003","journal-title":"J Exp Med"},{"issue":"12","key":"2019111818505035500_B36","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1080\/10428190701671044","article-title":"Parvovirus B19 acute infection and a reactivation of cytomegalovirus and herpesvirus 6 in a chronic myeloid leukemia patient during treatment with dasatinib (BMS-354825).","volume":"48","author":"Garc\u00eda-Mu\u00f1oz","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"2019111818505035500_B37","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/j.1365-2362.2009.02206.x","article-title":"Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily.","volume":"39","author":"Sillaber","year":"2009","journal-title":"Eur J Clin Invest"},{"issue":"9","key":"2019111818505035500_B38","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1056\/NEJMoa0903029","article-title":"A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults.","volume":"362","author":"French","year":"2010","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111818505035500_B39","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S1521-6616(03)00092-5","article-title":"Functional analysis of human memory B-cell subpopulations: IgD+CD27+ B cells are crucial in secondary immune response by producing high affinity IgM.","volume":"108","author":"Shi","year":"2003","journal-title":"Clin Immunol"},{"issue":"1","key":"2019111818505035500_B40","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1034\/j.1600-065X.2000.00607.x","article-title":"B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms.","volume":"176","author":"Vos","year":"2000","journal-title":"Immunol Rev"},{"issue":"8","key":"2019111818505035500_B41","doi-asserted-by":"crossref","first-page":"5306","DOI":"10.4049\/jimmunol.181.8.5306","article-title":"Human memory B lymphocyte subsets fulfill distinct roles in the anti-polysaccharide and anti-protein immune response.","volume":"181","author":"Moens","year":"2008","journal-title":"J Immunol"},{"issue":"12","key":"2019111818505035500_B42","doi-asserted-by":"crossref","first-page":"4758","DOI":"10.1182\/blood.V92.12.4758","article-title":"Lineage involvement of stem cells bearing the Philadelphia chromosome in chronic myeloid leukemia in the chronic phase as shown by a combination of fluorescence-activated cell sorting and fluorescence in situ hybridization.","volume":"92","author":"Takahashi","year":"1998","journal-title":"Blood"},{"issue":"15","key":"2019111818505035500_B43","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1182\/blood-2011-03-341693","article-title":"A phase 1 study of imatinib for corticosteroid-dependent\/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies.","volume":"118","author":"Chen","year":"2011","journal-title":"Blood"},{"issue":"11","key":"2019111818505035500_B44","doi-asserted-by":"crossref","first-page":"6033","DOI":"10.1021\/pr1008527","article-title":"Proteomics analysis of cellular imatinib targets and their candidate downstream effectors.","volume":"9","author":"Breitkopf","year":"2010","journal-title":"J Proteome Res"},{"issue":"33","key":"2019111818505035500_B45","doi-asserted-by":"crossref","first-page":"13283","DOI":"10.1073\/pnas.0702654104","article-title":"The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.","volume":"104","author":"Hantschel","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"2019111818505035500_B46","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1600-065X.2008.00748.x","article-title":"Tyrosine kinases and their substrates in B lymphocytes.","volume":"228","author":"Kurosaki","year":"2009","journal-title":"Immunol Rev"},{"issue":"3","key":"2019111818505035500_B47","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1084\/jem.20082100","article-title":"PLC-gamma2 is essential for formation and maintenance of memory B cells.","volume":"206","author":"Hikida","year":"2009","journal-title":"J Exp Med"},{"issue":"2","key":"2019111818505035500_B48","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.molimm.2008.08.278","article-title":"Btk regulates localization, in vivo activation, and class switching of anti-DNA B cells.","volume":"46","author":"Halcomb","year":"2008","journal-title":"Mol Immunol"},{"issue":"9","key":"2019111818505035500_B49","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2165\/11593320-000000000-00000","article-title":"Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.","volume":"50","author":"Di Gion","year":"2011","journal-title":"Clin Pharmacokinet"},{"issue":"14","key":"2019111818505035500_B50","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/122\/2\/227\/1371552\/227.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/122\/2\/227\/1371552\/227.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T05:40:27Z","timestamp":1715406027000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/122\/2\/227\/31688\/Tyrosine-kinase-inhibitors-impair-Bcell-immune"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,11]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,7,11]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-11-465039","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,11]]}}}